McDonald’s will begin serving vegan spam dubbed OmniPork Luncheon Meat as part of its breakfast menu in Shanghai, Guangzhou, and Shenzhen.
The OmniPork Luncheon Meat was rolled out to 280 McDonald’s locations in Hong Kong and Macau last October.
It is a plant-based version of Hormel’s popular canned meat made of soybeans, wheat, beets, and coconut oil and manufactured by OmniFoods, a Hong Kong-based company founded by David Yeung, the entrepreneur behind social enterprise Green Monday.
The positive response prompted McDonald’s to offer this plant-based option in other Asian markets.
A growing number of Chinese consumers are seeking food choices based on health, environmental and ethical reasons.
China’s alternative meat industry is a key target market for several international plant-based players.
Last year, Starbucks, offered a plant-based menu from Beyond Meat, and Omnipork in its 4,200 locations across China.
KFC, Taco Bell, and Pizza Hut followed suit, adding Beyond Meat products to its menu at five locations in Beijing, Chengdu, Hangzhou, and Shanghai.
Other plant-based food and beverage that have entered the Chinese food sector include Eat JUST Inc. and Oatly AB.


First Western Ship Transits Strait of Hormuz Since Iran War Began
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



